Moreover, the discharge of chemokines and adhesion mediators from injured IECs has been blocked by RIPK1 inhibitor treatment [72], implying that the pathogenesis of IBD is greatly aided by the activity of RIPK1. This evidence concerns the gene RIPK1 and inflammatory bowel disease.